Research | malecare.org

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT. However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By Malecare|2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Toxicity Analysis of Lymph Node Irradiation for Men with Prostate Cancer Treated with IMRT

The standard of treatment for men who have a localized recurrence in lymph nodes (LN) after surgery is intensity modulated radiation therapy (IMRT) as well as with men who have high-risk prostate cancer which includes cancer in both the prostate and seminal vesicles (SV). As with all treatments the use of IMRT comes with many [...]

By Malecare|2017-10-19T10:48:30-04:00March 17th, 2014|adjuvant therapy, Advanced Prostate Cancer, Drugs & Treatments, Radiotherapy, Research, salvage therapy, Uncategorized, Understanding APC|1 Comment

Analyzing Time to Developing Castration-Resistant Prostate Cancer and Overall Survival after Initiating Androgen Deprivation Therapy (ADT)

There are different methods of performing ADT; these methods include continuous or intermittent as well as differences in the actual blockade itself. Understanding the superior schedule as well as the superior combination of drugs can both delay the onset to castrate resistance as well as provide for a longer overall survival (OS). In a research [...]

By Malecare|2017-10-19T10:48:31-04:00March 11th, 2014|Advanced Prostate Cancer, CAB, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|4 Comments

Circulating Tumor Cell Enumeration in Metastatic Neuroendocrine Prostate Cancer and Castration-Resistant Prostate Cancer

An uncommon, but very aggressive form of prostate cancer is known as Neuroendocrine prostate cancer (NEPC). It is generally accepted that Circulating Tumor Cell (CTC) counts as measured by CellSearch (a method to catch and count these cells in the blood) are prognostic for most men with metastatic prostate cancer (mPC), but are not well [...]

By Malecare|2017-10-19T10:48:35-04:00February 12th, 2014|Advanced Prostate Cancer, CTCs, General Information, neuroendocrine prostate cancer, Research, Uncategorized, Understanding APC|0 Comments

NCI Director Out of Touch with His Agency and with the Major Characteristics of Breast & Prostate Cancer Funding

Out-takes from an Interview in August 2013 with Brian Lamb, a journalist and the founder, executive chairman, and now retired CEO of C-SPAN which provides coverage of the U,S. Congress as well as other public affairs events and Francis Collins an American physican-genetist who currently is the Director of the National Institute of Health (NIH) in Bethesda, Maryland. [...]

By Malecare|2014-01-24T13:57:58-05:00January 24th, 2014|Advanced Prostate Cancer, Advocacy, NCI, Prostate Ponderings, Research, Uncategorized|2 Comments